Synchron

Synchron
Coolcaesar · CC BY-SA 3.0 · source
Name	Synchron
Type	Private
Founded	2012
Founder	Thomas Oxley
Headquarters	Sydney, Australia and New York City
Industry	Neurotechnology, Medical devices
Products	Stentrode
Key people	Thomas Oxley, Nick Opie

Synchron is a neurotechnology company focused on implantable brain–computer interface devices intended to enable communication and control for patients with paralysis. The company developed a leadless, endovascular neural interface designed to be implanted via blood vessels to record neural signals without open cranial surgery. Synchron's work intersects with clinical neuroscience, interventional neuroradiology, medical device regulation, and technology commercialization.

History

Founded in 2012 by Thomas Oxley, the company emerged from research collaborations between Mount Sinai Health System, St. Vincent's Hospital, Sydney, and academic labs at University of Melbourne and St. Vincent's Institute of Medical Research. Early preclinical work built on vascular neuromodulation and intracranial recording studies that involved teams from Harvard Medical School, Massachusetts General Hospital, and Monash University. In 2016 Synchron secured seed and series A funding from investors including Allianz X and Founders Fund-associated groups, later attracting venture capital from Khosla Ventures and strategic partners in the medical device sector. Clinical translation advanced with trials registered in Australia and the United States, leveraging approvals from Therapeutic Goods Administration processes in Australia and investigational device exemptions from the Food and Drug Administration. Public milestones included first-in-human implants and demonstrations of assistive communication control, which were reported alongside peer-reviewed publications and presentations at meetings such as the Society for Neuroscience and the International Stroke Conference.

Technology

The company's primary device, the Stentrode, is an endovascular neural interface built on stent-based scaffolding and microelectrode arrays inspired by vascular stenting techniques used by Cardiology and Interventional Neuroradiology clinicians. The device is delivered via catheter through the jugular vein into cerebral venous structures, using procedural workflows similar to those practiced for cerebral venous sinus stenting and mechanical thrombectomy. Recording electrodes integrated into the stent capture local field potentials and multiunit activity from adjacent cortical areas, with signal processing pipelines implemented using algorithms comparable to those developed in labs at Johns Hopkins University, MIT Media Lab, and University of California, San Francisco. Wireless telemetry, power management, and implant biocompatibility draw on materials science contributions from MIT, Imperial College London, and industrial partners experienced in neuromodulation such as Medtronic and Boston Scientific. The minimally invasive approach contrasts with paddle and depth electrodes developed by teams at Brown University and University of Pittsburgh Medical Center, aiming to reduce risks associated with craniotomy and parenchymal implants while enabling chronic recordings for brain–computer interface control.

Clinical Applications

Synchron aims to translate its implantable interface into therapeutic and assistive solutions for people with paralysis due to amyotrophic lateral sclerosis, spinal cord injury, stroke, and neurodegenerative disorders treated at centers like Neurorehabilitation Unit, Johns Hopkins Hospital and Massachusetts General Hospital. Clinical demonstrations emphasized restoration of communication through neural decoding enabling typing and cursor control, comparable to research from groups at Stanford University and Carnegie Mellon University. Trials have explored integration with external assistive technologies such as smartphones, tablet computers from Apple Inc. and alternative communication devices used by speech therapy programs at Mayo Clinic. Rehabilitation workflows involve multidisciplinary teams including neurologists from Royal Melbourne Hospital and neurointerventionists trained in endovascular procedures used at Mount Sinai Health System. Potential future indications discussed in the literature include closed-loop neuromodulation for movement disorders treated at centers like UCL Queen Square Institute of Neurology and neuroprosthetic control akin to projects at DARPA-funded programs.

Safety and Ethics

Safety considerations center on vascular implantation risks familiar to practitioners of endovascular neurosurgery and interventional cardiology, such as thrombosis, hemorrhage, infection, and device migration. Ethical discussions draw on frameworks established by bioethics committees at National Institutes of Health, institutional review boards at University of Melbourne, and international statements from organizations like the World Medical Association. Key topics include informed consent for participants with impaired communication, long-term device explantation policies informed by precedents from neuroprosthetics research, data privacy and neural data ownership debated in forums at Stanford Law School and Harvard School of Public Health, and equitable access to advanced therapies highlighted by policy analysts at OECD and World Health Organization. Clinical oversight typically involves multidisciplinary safety monitoring boards similar to those used by multinational device trials and reporting pathways to regulators like the Food and Drug Administration and Therapeutic Goods Administration.

Regulatory and Commercial Development

Commercialization activities have pursued regulatory clearances and reimbursement pathways using precedents from companies such as Medtronic and Abbott Laboratories. The company engaged with device regulation frameworks at the Food and Drug Administration for investigational device exemptions and early feasibility studies, and with the Therapeutic Goods Administration for Australian clinical use. Strategic partnerships, licensing negotiations, and manufacturing scale-up have been informed by collaborations with contract manufacturing organizations and clinical partners across North America, Europe, and Asia-Pacific. Investor relations and public communications have paralleled other neurotechnology firms that transitioned from academia to market, with milestones announced alongside presentations at industry conferences like CES and Neurotech Investing Summit.

Category:Neurotechnology companies